{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:51:09Z","timestamp":1782478269062,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00120-026-02843-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:49:11Z","timestamp":1779194951000},"page":"749-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rezidivierende Urolithiasis\u00a0\u2013 Wann Therapie eskalieren? Wann absetzen?","Management of recurrent urolithiasis: indications for therapy escalation and discontinuation"],"prefix":"10.1007","volume":"65","author":[{"given":"Roman","family":"Herout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neisius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2843_CR1","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/ckj\/sfad126","volume":"16","author":"L Cirillo","year":"2023","unstructured":"Cirillo\u00a0L, Becherucci\u00a0F, Windpessl\u00a0M (2023) Kidney stones and thiazide diuretics: revisiting old assumptions in light of the NOSTONE trial. Clin Kidney\u00a0J 16:1372\u20131374. https:\/\/doi.org\/10.1093\/ckj\/sfad126","journal-title":"Clin Kidney J"},{"key":"2843_CR2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.juro.2015.10.082","volume":"195","author":"CA Dauw","year":"2016","unstructured":"Dauw\u00a0CA, Yi\u00a0Y, Bierlein\u00a0MJ et\u00a0al (2016) Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones. J\u00a0Urol 195:648\u2013652. https:\/\/doi.org\/10.1016\/j.juro.2015.10.082","journal-title":"J Urol"},{"key":"2843_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa2209275","volume":"388","author":"NA Dhayat","year":"2023","unstructured":"Dhayat\u00a0NA, Bonny\u00a0O, Roth\u00a0B et\u00a0al (2023) Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. N\u00a0Engl J Med 388:781\u2013791. https:\/\/doi.org\/10.1056\/NEJMoa2209275","journal-title":"N Engl J Med"},{"key":"2843_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109526","volume":"36","author":"K Gianmoena","year":"2021","unstructured":"Gianmoena\u00a0K, Gasparoni\u00a0N, Jashari\u00a0A et\u00a0al (2021) Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a\u00a0risk factor for hyperoxaluria. Cell Reports 36:109526. https:\/\/doi.org\/10.1016\/j.celrep.2021.109526","journal-title":"Cell Reports"},{"key":"2843_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/end.2019.0040","volume":"33","author":"D Golomb","year":"2019","unstructured":"Golomb\u00a0D, Nevo\u00a0A, Goldberg\u00a0H et\u00a0al (2019) Long-Term Adherence to Medications in Secondary Prevention of Urinary Tract Stones. J\u00a0Endourol 33:469\u2013474. https:\/\/doi.org\/10.1089\/end.2019.0040","journal-title":"J Endourol"},{"key":"2843_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03818-y","author":"R Herout","year":"2021","unstructured":"Herout\u00a0R, Baunacke\u00a0M, Groeben\u00a0C et\u00a0al (2021) Contemporary treatment trends for upper urinary tract stones in a total population analysis in Germany from 2006 to 2019: will shock wave lithotripsy become extinct? World J Urol. https:\/\/doi.org\/10.1007\/s00345-021-03818-y","journal-title":"World J Urol"},{"key":"2843_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/s0302-2838(03)00415-9","volume":"44","author":"A Hesse","year":"2003","unstructured":"Hesse\u00a0A, Br\u00e4ndle\u00a0E, Wilbert\u00a0D et\u00a0al (2003) Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. Eur Urol 44:709\u2013713. https:\/\/doi.org\/10.1016\/s0302-2838(03)00415-9","journal-title":"Eur Urol"},{"key":"2843_CR8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep4.1899","volume":"6","author":"Y Huber","year":"2022","unstructured":"Huber\u00a0Y, Schulz\u00a0A, Schmidtmann\u00a0I et\u00a0al (2022) Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. Hepatol Commun 6:1457\u20131466. https:\/\/doi.org\/10.1002\/hep4.1899","journal-title":"Hepatol Commun"},{"key":"2843_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10050836","volume":"10","author":"M Ilzkovitz","year":"2022","unstructured":"Ilzkovitz\u00a0M, Kayembe\u00a0EE, Geers\u00a0C, Pozdzik\u00a0A (2022) Kidney Stones, Proteinuria and Renal Tubular Metabolic Acidosis: What Is the Link? Healthcare (Basel) 10:836. https:\/\/doi.org\/10.3390\/healthcare10050836","journal-title":"Healthcare (Basel)"},{"key":"2843_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5049\/EBP.2021.19.2.29","volume":"19","author":"HJ Kim","year":"2021","unstructured":"Kim\u00a0HJ (2021) Metabolic Acidosis in Chronic Kidney Disease: Pathogenesis, Clinical Consequences, and Treatment. Electrolyte Blood Press 19:29\u201337. https:\/\/doi.org\/10.5049\/EBP.2021.19.2.29","journal-title":"Electrolyte Blood Press"},{"key":"2843_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.ackd.2008.10.002","volume":"16","author":"Y Lotan","year":"2009","unstructured":"Lotan\u00a0Y (2009) Economics and cost of care of stone disease. Adv Chronic Kidney Dis 16:5\u201310. https:\/\/doi.org\/10.1053\/j.ackd.2008.10.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"2843_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s12325-020-01587-5","volume":"38","author":"BF Palmer","year":"2021","unstructured":"Palmer\u00a0BF, Kelepouris\u00a0E, Clegg\u00a0DJ (2021) Renal Tubular Acidosis and Management Strategies: A Narrative Review. Adv Ther 38:949\u2013968. https:\/\/doi.org\/10.1007\/s12325-020-01587-5","journal-title":"Adv Ther"},{"key":"2843_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010057.pub2","volume":"2015","author":"R Phillips","year":"2015","unstructured":"Phillips\u00a0R, Hanchanale\u00a0VS, Myatt\u00a0A et\u00a0al (2015) Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev 2015:CD010057. https:\/\/doi.org\/10.1002\/14651858.CD010057.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2843_CR14","doi-asserted-by":"crossref","unstructured":"Qian X, Wan J, Xu J et\u00a0al. (2022) Epidemiological Trends of Urolithiasis at the Global, Regional, and National Levels: A\u00a0Population-Based Study. Int J Clin Pract 2022:6807203. https:\/\/doi.org\/10.1155\/2022\/6807203","DOI":"10.1155\/2022\/6807203"},{"key":"2843_CR15","doi-asserted-by":"publisher","DOI":"10.1159\/000525180","author":"A Reicherz","year":"2022","unstructured":"Reicherz\u00a0A, Rausch\u00a0P, Herout\u00a0R et\u00a0al (2022) Prophylaxis of Recurrent Stone Disease in Outpatient Clinics in Germany: A Quality-of-Care Concern. Urol Int. https:\/\/doi.org\/10.1159\/000525180","journal-title":"Urol Int"},{"key":"2843_CR16","doi-asserted-by":"publisher","unstructured":"Robert Koch Institute (2025) Verbreitung von Adipositas und Rauchen bei Erwachsenen in Deutschland \u2013 Entwicklung von 2003 bis 2023. https:\/\/doi.org\/10.25646\/12990","DOI":"10.25646\/12990"},{"key":"2843_CR17","doi-asserted-by":"crossref","unstructured":"Seitz C, Bach T, Bader M et\u00a0al (2018) S2k-Leitlinie zur Diagnostik, Therapie und Metaphylaxe der Urolithiasis (AWMF Registernummer 043 - 025). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-025l_S2k_Diagnostik_Therapie_Metaphylaxe_Urolithiasis_2019-07_1.pdf. Accessed 4.4.2026","DOI":"10.1007\/s00120-019-01033-7"},{"key":"2843_CR18","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00120-011-2619-2","volume":"50","author":"R Siener","year":"2011","unstructured":"Siener\u00a0R, Laube\u00a0N, Strohmaier\u00a0WL (2011) Recurrence prevention of urolithiasis with respect to economic aspects. Urologe\u00a0A 50:1276\u20131282. https:\/\/doi.org\/10.1007\/s00120-011-2619-2","journal-title":"Urologe A"},{"key":"2843_CR19","unstructured":"Skolarikos A, Davis N, Gambaro G (2026) European Association of Urology Guidelines on Urolithiasis. https:\/\/uroweb.org\/guidelines\/urolithiasis. Accessed 4.4.2026"},{"key":"2843_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","volume":"35","author":"I Sorokin","year":"2017","unstructured":"Sorokin\u00a0I, Mamoulakis\u00a0C, Miyazawa\u00a0K et\u00a0al (2017) Epidemiology of stone disease across the world. World J Urol 35:1301\u20131320. https:\/\/doi.org\/10.1007\/s00345-017-2008-6","journal-title":"World J Urol"},{"key":"2843_CR21","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00120-006-1225-1","volume":"45","author":"M Straub","year":"2006","unstructured":"Straub\u00a0M, Hautmann\u00a0RE (2006) Urolithiasis \u2013 moderne Metaphylaxe wieder ein Thema. Urologe 45:1385\u20131386. https:\/\/doi.org\/10.1007\/s00120-006-1225-1","journal-title":"Urologe"},{"key":"2843_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000052367","volume":"37","author":"WL Strohmaier","year":"2000","unstructured":"Strohmaier\u00a0WL (2000) Course of calcium stone disease without treatment. What can we expect? Eur Urol 37:339\u2013344. https:\/\/doi.org\/10.1159\/000052367","journal-title":"Eur Urol"},{"key":"2843_CR23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1007\/s00120-006-1220-6","volume":"45","author":"WL Strohmaier","year":"2006","unstructured":"Strohmaier\u00a0WL (2006) \u00d6konomische Aspekte der evidenzbasierten Harnsteinmetaphylaxe. Urologe 45:1406\u20131409. https:\/\/doi.org\/10.1007\/s00120-006-1220-6","journal-title":"Urologe"},{"key":"2843_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.aju.2012.02.002","volume":"10","author":"WL Strohmaier","year":"2012","unstructured":"Strohmaier\u00a0WL (2012) Economics of stone disease\/treatment. Arab Journal of Urology 10:273\u2013278. https:\/\/doi.org\/10.1016\/j.aju.2012.02.002","journal-title":"Arab Journal of Urology"},{"key":"2843_CR25","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/j.1523-1755.2005.00516.x","volume":"68","author":"EN Taylor","year":"2005","unstructured":"Taylor\u00a0EN, Stampfer\u00a0MJ, Curhan\u00a0GC (2005) Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68:1230\u20131235. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00516.x","journal-title":"Kidney Int"},{"key":"2843_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-01017-4","volume":"22","author":"K Wang","year":"2022","unstructured":"Wang\u00a0K, Ge\u00a0J, Han\u00a0W et\u00a0al (2022) Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis. BMC Urol 22:62. https:\/\/doi.org\/10.1186\/s12894-022-01017-4","journal-title":"BMC Urol"},{"key":"2843_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1089\/end.2015.0567","volume":"30","author":"Y Wong","year":"2016","unstructured":"Wong\u00a0Y, Cook\u00a0P, Roderick\u00a0P, Somani\u00a0BK (2016) Metabolic Syndrome and Kidney Stone Disease: A Systematic Review of Literature. J\u00a0Endourol 30:246\u2013253. https:\/\/doi.org\/10.1089\/end.2015.0567","journal-title":"J Endourol"},{"key":"2843_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf244","volume":"18","author":"A Zomorodian","year":"2025","unstructured":"Zomorodian\u00a0A, Moe\u00a0OW (2025) Citrate and calcium kidney stones. Clin Kidney\u00a0J 18:sfaf244. https:\/\/doi.org\/10.1093\/ckj\/sfaf244","journal-title":"Clin Kidney J"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02843-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:36:45Z","timestamp":1782477405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02843-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02843-2","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Herout gibt an, dass er Honorare f\u00fcr Vortr\u00e4ge von den Firmen Astellas, AstraZeneca, Bristol-Meyers Squibb, Novartis, Desitin und Wellspect erhalten hat. Reiseunterst\u00fctzung bzw. Sponsoring von den Firmen Merck, Intuitive surgical und Medtronic. Nichtfinanzielle Interessen: Mitglied im Arbeitskreis Harnsteine der DGU, Oberarzt am Universit\u00e4tsklinikum Carl Gustav Carus Dresden, Klinik f\u00fcr Urologie. Mitgliedschaften: DGU, DGRU, GeSRU, EAU. A.\u00a0Neisius gibt an, dass er Honorare f\u00fcr Vortr\u00e4ge von den Firmen Aristo, Astellas, Astra Zeneca, BMS, Boston Scientific, Desitin, EMS, Ipsen, Johnson&Johnson, MSD, und Pfizer erhalten hat. Nichtfinanzielle Interessen: Vorsitzender des Arbeitskreis Harnsteine der DGU, Mitglied des Arbeitskreis Harnsteine der europ\u00e4ischen Gesellschaft f\u00fcr Urologie (EAU), Chefarzt der Urologie am Krankenhaus der Barmherzigen Br\u00fcder in Trier. Mitgliedschaften: DGU, DGRU, GeSRU, EAU, Endourological Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}